KRAS and colorectal cancer: The predictive value of genomic mutations in colorectal cancer has previously been investigated; the studies concluded that KRAS, as well as RAS, BRAF and PIK3CA mutations, are predictive of tumor response to anti-EGFR therapy [17,18,21,22,23,24,25].